Seventure Partners said April 11 that Professor Denise Kelly has joined as an Investment Advisor, while Oxana Kukhaneva has been appointed Venture Partner. Kelly was previously at the Rowett Institute, University of Aberdeen where she was a Professor of Immunology and Microbiology. Kukhaneva was with Inventages Venture Capital, where she was Investment Manager of the investment team. Seventure is a subsidiary of Natixis Global Asset Management.
Paris, France – 11 April 2016 – Seventure Partners, one of Europe’s leaders in financing innovation, today announced that it has furthered strengthened its Life Sciences team with two new appointments; Professor Denise Kelly joins as an Investment Advisor whilst Oxana Kukhaneva has been appointed Venture Partner.
Ms. Kukhaneva joins Seventure from Inventages Venture Capital, where she was Investment Manager of the investment team. Oxana brings over 12 years’ experience in private equity investment in venture and growth in healthcare, nutrition and consumer goods. Born and raised in Russia, she started her career in project finance and business development, working for a software start-up company. Oxana holds a BA in International Relations and Affairs and a BS in Economics from the Moscow State Institute of International Relations MFA Russia MGIMO, as well as an MA and MBA from the International Institute for Management Development in Switzerland.
Professor Kelly joins Seventure from the Rowett Institute, University of Aberdeen where she was a Professor of Immunology and Microbiology for over 25 years. In tandem, she held the roles of CEO and CSO at GT Biologics Ltd, a spin-out of the Rowett Institute, from 2008-2015. Professor Kelly holds a BSc and PhD from the Queen’s University, Belfast and gained her Emeritus Professorship from the University of Aberdeen. Her significant experience in gut microbiology and immunology brings key expertise to Seventure, where her main focus will be on microbiome investments.
Welcoming Oxana and Denise to the team, Isabelle de Cremoux, CEO of Seventure Partners, said: “Through our innovative Health for Life Capital, we continue to invest in companies who are working at the cutting edge of food, nutrition, pharma and more broadly human health. To ensure we have the best talent and can make the best, most informed investments, we are expanding our team to reflect the experience and specialist expertise required.”
About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.
In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
For more details: www.seventure.com
For more details: www.seventure.fr